Angiotensin II receptor blockers in treatment of hypertensive patients with metabolic disorders

The aim of the research: the clinical effectiveness of Russian form of Angiotensine II receptor blocker Valsartan – Valsafors in hypertension associated with purine and carbohydrate metabolism disorders patients’ treatment was studied. Material and methods: 45 men aged 40–70 years with hypertension of 1–3 stage associated with hyperuricemy and glucose intolerance were investigated. Valsafors as monotherapy or as component of combine therapy was prescript to all patients for 12 weeks. The main results: it has been revealed that Valsafors’ treatment was associated with clearly antihypertensive effect and positive influence on purine and carbohydrate metabolism levels as well as insulin resistance. Good tolerance and effective Valsafors interaction with other antihypertensive agents were noted. Conclusion: it has been shown that Valsafors can be successfully used as drug of choice in hypertension associated with purine and carbohydrate metabolism disorders patients’ treatment.

1. Bilchenko A.V. Hyperuricemia as a risk factor of cardiovaskular morbidity and mortality.// Health of Ukraine, Theme No. 2009, June, p. 46-48. (in Russian)

2. Britov A.N., Eliseev N.A., Deev A.D. et all. Relationship between hypertension, metabolic desorders and urate nephropathy.// Therapeutic Archives, 2006, 5: 41–45. (in Russian)

3. Diagnosis and treatment of metabolic syndrome. Russian recommendations. Moscow, 2007. Cardiovaskular Therapy and Prevention, 2007; app. 2:3-26. (in Russian)

4. Lebedeva M.V., Balkarov I.M., Shovskaya T.N. Urate nephropathy - a cause of reversible Renal failure in a young adult patient. // Therapeutic Archives, 2006, 5: 69–71. (in Russian)

5. Olbinskaya L.I., Hapaeva B.A. Blood pressure monitoring in diagnostic and treatment of hypertension.// Guidance for doctors and senior students, Moscow, 1997, 35 p. (in Russian)

6. Samorodskaya I.V. Cardiovascular morbidity and cardiovascular events risk factors in the Russian Federation.// Cardiovaskular Therapy and Prevention, 2005, №4, part  II. - p. 94-100. (in Russian)

7. Hoieggen A., Alderman M.N., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study // Kidney Int. 2004. 65. 1041–1049.

8. Kjeldsen S.E., Julius S., Mancia G et al. Effects of  valsartan  compared  to  amlodipine  on  preventing type 2 diabetes in high–risk hypertensive patients: the VALUE trial // J. Hypertens. 2006. 24. 1405–1412.

9. Mancia G., De Backer G., Dominiczak A. et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH)  and  of  the  European  Society  of  Cardiology (ESC) // Eur. Heart J. 2007. 28. 1462–1536.

10. Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. 1985. 28. 412–419.

11. Reappraisal of European guidelines on hypertension management: a ESH Task Force document 2009 // J. Hypertens. 2009. 27. 2121–2158.

12. Rho Y.H., Choi S.J., Lee Y.H. et al. The prevalence of metabolic syndrome in patients with gout: A multicenter study // J. Korean Med. Sci. 2005. 20. 1029–1033.

13. Top C., Cingozbay B.Y., Terekeci H. et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension // J. Int. Med. Res. 2002. 30. 15– 20.

14. Weycker D., Edelsberg J., Vincze G. et al. Risk of diabetes in a real–world setting among patients initiating antihypertensive therapy with valsartan or amlodipine // J. Hum. Hypertens. 2007. 21. 374–380.

Yakhontov D.A. – doctor of medical sciences, professor of the chair for hospital therapy and clinical pharmacology, e-mail: mich99@mail.ru

Orlovetskaya E.V. – cardiologist, e-mail: orl.elena@mail.ru